NASDAQ Framework: Inari Medical Inc.

Medical device company specializing in thrombectomy devices 1.

Inari Medical, Inc., headquartered in Irvine, California, is a medical device company focused on developing innovative, minimally invasive, catheter-based mechanical thrombectomy devices and accessories to treat patients suffering from venous diseases 2 3. The company's product portfolio includes the ClotTriever system for deep vein thrombosis, the FlowTriever system for pulmonary embolism, the InThrill system for small vessel thrombosis, and the LimFlow system for chronic limb-threatening ischemia 4. Inari Medical is committed to improving patient outcomes through education, clinical research, and program development, aiming to establish its treatments as the standard of care for venous diseases 5.

2: Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. View Source3: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. The company's innovative devices are designed to remove blood clots and restore blood flow, contributing to the rapidly growing field of vascular therapy. View Source4: Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. View Source5: About Inari Medical, Inc.Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease and beyond. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram. View Source

UNKNOWN

The provided facts do not specify whether Inari Medical Inc. is still led by its founders or if the founders are heavily involved in the company's current operations.

MEDIUM RISK

Inari Medical Inc. has been involved in several insider sales and has faced legal issues, including a class action lawsuit and an investigation by the U.S. Department of Justice for potential violations of the Anti-Kickback Statute and Civil False Claims Act 6 7 8 9 10 11 12. Additionally, the company has received mixed ratings from analysts, with some downgrading the stock due to competitive concerns 13 14 15. Despite these challenges, the company continues to innovate and expand its product offerings, and it is expected to release its second quarter 2024 financial results soon 16 17 18. Given these factors, Inari Medical Inc.'s financial situation can be considered medium risk.

6: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 14.67 percent of Inari Medical Inc shares are owned by insiders, and 90.85 percent are held by financial institutions. Hoffman William, the Director at Inari Medical Inc (NARI) has sold 60,000 shares of firm on Jul 16 ’24 at a price of $56.74 against the total amount of $3.4 million. In another inside trade, Tu Thomas, Chief Medical Officer of Inari Medical Inc (NASDAQ:NARI) sold 3,480 shares of the firm on Jul 16 ’24 for a total worth of $0.19 million at a price of $55.16. An inside trade which took place on Jul 15 ’24, Chief Medical Officer of Inari Medical Inc Tu Thomas sold 16,520 shares of firm against total price of $0.91 million at the cost of $55.09 per share. View Source7: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 14.67 percent of Inari Medical Inc shares are owned by insiders, and 90.99 percent are held by financial institutions. Hoffman William, the Director at Inari Medical Inc (NARI) has sold 20,000 shares of firm on Jul 01 ’24 at a price of $50.15 against the total amount of $1.0 million. In another inside trade, Hykes Andrew, President and CEO of Inari Medical Inc (NASDAQ:NARI) sold 3,000 shares of the firm on Jul 01 ’24 for a total worth of $0.15 million at a price of $50.08. An inside trade which took place on Jun 21 ’24, Director of Inari Medical Inc Chambers Rebecca sold 260 shares of firm against total price of $11957.0 at the cost of $45.99 per share. View Source8: LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming July 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) common stock between March 10, 2021 through February 28, 2024, inclusive (the “Class Period”). View Source9: LOS ANGELES, July 1, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Inari Medical, Inc. ("Inari" or the "Company") (NASDAQ: NARI). View Source10: The complaint filed alleges that, throughout the Class Period, Defendants: (1) repeatedly touted Inari's financial results and the success of its product sales, but failed to disclose that these numbers were inflated by bribes and other improper and illegal payments to healthcare providers; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. View Source11: On February 29, 2024, Inari announced that it had received a civil investigative demand from the U.S. Department of Justice “in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act” requesting information and documents “primarily relating to meals and consulting service payments provided to health care professionals.” View Source12: The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants: (1) repeatedly touted Inari’s financial results and the success of its product sales, but failed to disclose that these numbers were inflated by bribes and other improper and illegal payments to healthcare providers; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. View Source13: Needham raised the price target for the Inari Medical Inc (NASDAQ:NARI) stock from “a Buy” to “a Hold”. The rating was released on July 18, 2024, according to finviz. We previously noted in another research note published on February 29, 2024 by Piper Sandler that downgraded the stock from an Overweight to a Neutral with a price target of $55 for NARI stock. The research report from Needham has initiated the stock to Buy, with a price target set at $72. The stock was initiated by Robert W. Baird, who disclosed in a research note on July 19, 2023, to Outperform and set the price objective to $79. In their research brief published October 12, 2022, Jefferies analysts initiated the Inari Medical Inc stock to Buy with a price target of $88. View Source14: Piper Sandler lowered the price target for the Inari Medical Inc (NASDAQ:NARI) stock from “an Overweight” to “a Neutral”. The rating was released on February 29, 2024, according to finviz. The research report from Robert W. Baird has initiated the stock to Outperform, with a price target set at $79. The stock was initiated by Jefferies, who disclosed in a research note on October 12, 2022, to Buy and set the price objective to $88. In their research brief published September 29, 2022, Berenberg analysts initiated the Inari Medical Inc stock to Buy with a price target of $85. View Source15: Needham cuts Inari to hold, cites competitive concerns View Source16: IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024 financial results on Tuesday, July 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. View Source17: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. The company's innovative devices are designed to remove blood clots and provide solutions to improve patient outcomes in the venous system. View Source18: Inari Medical to Announce Second Quarter 2024 Financial Results View Source

NO

The provided facts do not indicate that Inari Medical Inc. is launching any new product offerings.

Inari Medical Inc. is focused on expanding its innovative product offerings and improving patient outcomes through a robust product roadmap and strategic initiatives from 2024 to 2026. The company continues to develop and enhance its minimally invasive, catheter-based mechanical thrombectomy devices, including the ClotTriever system for deep vein thrombosis, the FlowTriever system for pulmonary embolism, the InThrill system for small vessel thrombosis, and the LimFlow system for chronic limb-threatening ischemia 19 20 21. Inari Medical is committed to leveraging its capabilities in education, clinical research, and program development to establish its treatments as the standard of care for venous diseases, aiming to transform the lives of patients suffering from these conditions 22 23.

19: Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. View Source20: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. The company's innovative devices are designed to remove blood clots and provide solutions to improve patient outcomes in the venous system. View Source21: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. The company's innovative devices are designed to remove blood clots and restore blood flow, contributing to the rapidly growing field of vascular therapy. View Source22: About Inari Medical, Inc.Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease and beyond. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram. View Source23: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. The company's innovative devices are designed to remove blood clots and provide solutions to improve patient outcomes in the venous system. View Source

Sources

1: Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. View Source2: Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. View Source3: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. The company's innovative devices are designed to remove blood clots and restore blood flow, contributing to the rapidly growing field of vascular therapy. View Source4: Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. View Source5: About Inari Medical, Inc.Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease and beyond. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram. View Source6: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 14.67 percent of Inari Medical Inc shares are owned by insiders, and 90.85 percent are held by financial institutions. Hoffman William, the Director at Inari Medical Inc (NARI) has sold 60,000 shares of firm on Jul 16 ’24 at a price of $56.74 against the total amount of $3.4 million. In another inside trade, Tu Thomas, Chief Medical Officer of Inari Medical Inc (NASDAQ:NARI) sold 3,480 shares of the firm on Jul 16 ’24 for a total worth of $0.19 million at a price of $55.16. An inside trade which took place on Jul 15 ’24, Chief Medical Officer of Inari Medical Inc Tu Thomas sold 16,520 shares of firm against total price of $0.91 million at the cost of $55.09 per share. View Source7: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 14.67 percent of Inari Medical Inc shares are owned by insiders, and 90.99 percent are held by financial institutions. Hoffman William, the Director at Inari Medical Inc (NARI) has sold 20,000 shares of firm on Jul 01 ’24 at a price of $50.15 against the total amount of $1.0 million. In another inside trade, Hykes Andrew, President and CEO of Inari Medical Inc (NASDAQ:NARI) sold 3,000 shares of the firm on Jul 01 ’24 for a total worth of $0.15 million at a price of $50.08. An inside trade which took place on Jun 21 ’24, Director of Inari Medical Inc Chambers Rebecca sold 260 shares of firm against total price of $11957.0 at the cost of $45.99 per share. View Source8: LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming July 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) common stock between March 10, 2021 through February 28, 2024, inclusive (the “Class Period”). View Source9: LOS ANGELES, July 1, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Inari Medical, Inc. ("Inari" or the "Company") (NASDAQ: NARI). View Source10: The complaint filed alleges that, throughout the Class Period, Defendants: (1) repeatedly touted Inari's financial results and the success of its product sales, but failed to disclose that these numbers were inflated by bribes and other improper and illegal payments to healthcare providers; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. View Source11: On February 29, 2024, Inari announced that it had received a civil investigative demand from the U.S. Department of Justice “in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act” requesting information and documents “primarily relating to meals and consulting service payments provided to health care professionals.” View Source12: The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants: (1) repeatedly touted Inari’s financial results and the success of its product sales, but failed to disclose that these numbers were inflated by bribes and other improper and illegal payments to healthcare providers; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. View Source13: Needham raised the price target for the Inari Medical Inc (NASDAQ:NARI) stock from “a Buy” to “a Hold”. The rating was released on July 18, 2024, according to finviz. We previously noted in another research note published on February 29, 2024 by Piper Sandler that downgraded the stock from an Overweight to a Neutral with a price target of $55 for NARI stock. The research report from Needham has initiated the stock to Buy, with a price target set at $72. The stock was initiated by Robert W. Baird, who disclosed in a research note on July 19, 2023, to Outperform and set the price objective to $79. In their research brief published October 12, 2022, Jefferies analysts initiated the Inari Medical Inc stock to Buy with a price target of $88. View Source14: Piper Sandler lowered the price target for the Inari Medical Inc (NASDAQ:NARI) stock from “an Overweight” to “a Neutral”. The rating was released on February 29, 2024, according to finviz. The research report from Robert W. Baird has initiated the stock to Outperform, with a price target set at $79. The stock was initiated by Jefferies, who disclosed in a research note on October 12, 2022, to Buy and set the price objective to $88. In their research brief published September 29, 2022, Berenberg analysts initiated the Inari Medical Inc stock to Buy with a price target of $85. View Source15: Needham cuts Inari to hold, cites competitive concerns View Source16: IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024 financial results on Tuesday, July 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. View Source17: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. The company's innovative devices are designed to remove blood clots and provide solutions to improve patient outcomes in the venous system. View Source18: Inari Medical to Announce Second Quarter 2024 Financial Results View Source19: Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. View Source20: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. The company's innovative devices are designed to remove blood clots and provide solutions to improve patient outcomes in the venous system. View Source21: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. The company's innovative devices are designed to remove blood clots and restore blood flow, contributing to the rapidly growing field of vascular therapy. View Source22: About Inari Medical, Inc.Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease and beyond. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram. View Source23: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. The company's innovative devices are designed to remove blood clots and provide solutions to improve patient outcomes in the venous system. View Source